GlassScriptPhysician profile
John Christopher Richey
NPI 1306455118
$11,674.27
in general payments reported to CMS, 2019-2025
30 companies · $34.42 in 2025
The $34.42 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,672 · 2022: $2,674 · 2023: $2,894 · 2024: $3,400 · 2025: $34.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,620 · Travel and Lodging: $1,617 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,619.64 |
| Travel and Lodging | $1,616.92 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,616.92 | 2024 | |
| Abbvie INC. | $1,289.02 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,050.83 | 2021-2024 | Rexulti, Nuedexta, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $935.12 | 2021-2024 | Trintellix |
| Axsome Therapeutics, INC. | $843.99 | 2022-2024 | Auvelity, Sunosi |
| Supernus Pharmaceuticals, INC. | $793.99 | 2021-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $790.97 | 2021-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $725.28 | 2021-2024 | Caplyta |
| Corium, LLC | $669.49 | 2021-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $602.15 | 2021-2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $431.37 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $307.81 | 2021-2024 | Spravato |
| Idorsia Pharmaceuticals US INC | $200.12 | 2023-2024 | Quviviq |
| Alkermes, INC. | $198.30 | 2022-2024 | Lybalvi |
| Merck Sharp & Dohme LLC | $162.47 | 2021-2023 | Belsomra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $159.80 | 2021-2023 | Aplenzin |
| Teva Pharmaceuticals USA, INC. | $141.55 | 2023-2024 | Uzedy, Austedo |
| Almatica Pharma LLC | $124.61 | 2023-2024 | Loreev Xr |
| Harmony Biosciences LLC | $101.84 | 2023-2024 | Wakix |
| Jazz Pharmaceuticals INC. | $96.53 | 2021-2023 | |
| Adlon Therapeutics L.P. | $95.07 | 2021 | |
| Neos Therapeutics, LP | $76.99 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $55.54 | 2021-2022 | |
| Noven Therapeutics, LLC | $40.08 | 2024 | Xelstrym, Secuado |
| Eisai INC. | $39.08 | 2021 | |
| Livanova USA, INC. | $38.12 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Tris Pharma INC | $30.59 | 2024 | Dyanavel Xr |
| Neurocrine Biosciences, INC. | $26.02 | 2023 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $19.57 | 2022 | |
| Alfasigma USA, INC. | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Richey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.